5 min read

Improving the Debarment Check Process in Publication Planning

By Steve Altschuler on Apr 26, 2022 4:30:00 PM

With all the hard work that goes into the complex and delicate process of medical innovation, the last thing pharmaceutical and biotech companies want is to see publication planning delayed by an incomplete or unnecessarily lengthy debarment check process.

Topics: Pharma publication planning
5 min read

The Challenges of Pharmaceutical Publication Planning

By Steve Altschuler on Apr 18, 2022 7:00:00 AM

Between 2010 and 2019, the number of new drugs approved for sale increased by 60 percent compared with the previous decade, with a peak of 59 new drugs approved in 2018.

Topics: Pharma publication planning
3 min read

Automating the approval process in Biotech and Pharma

By BP Logix on May 25, 2021 3:43:04 PM

Heavily regulated industries inherently have a lot of rules. The biotech and pharmaceutical industries are no exception. Adhering to complex regulations requires significant amounts of administrative work to ensure that the proper directives are being followed. Extensive regulations also present significant risks of hefty fines for noncompliance. Failed clinical trials also present a significant risk to pharmaceutical companies and can cost billions a year. 

Topics: Pharma
3 min read

Improving collaboration workflows for drug approval

By BP Logix on May 11, 2021 11:22:37 AM

Time to market has a significant impact on profits, particularly in the ultra-competitive life science and pharmaceutical industries. Delays in bringing products to market can lead to deferred or missed revenues. But, the heavily regulated drug approval process requires a variety of inputs and approvals to validate each step of the process, extending the development period. While there are many hurdles to clear, skipping any of these steps can expose operations up to compliance risks. 

Topics: Pharma
5 min read

How Low-Code Automation can help Pharma Evolve - 5 Key Imperatives

By Girish Pashilkar on Apr 15, 2021 2:48:09 PM

The average cost of developing a drug is $2.6 Billion and rising, with a 12% success rate1.  As pharma companies look to 2021 and beyond, the Medical Affairs, Commercial and Regulatory affairs teams will be collaborating more closely amongst themselves and with third parties to accelerate new product launches while navigating burgeoning compliance requirements.  What role can technology play?  In this blogpost we explore how low-code software platforms can enable a competitive advantage learning from the experience of one of the largest Pharmaceutical companies in the world.  

Topics: Pharma
BP Logix Process Director Reviews